3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Surveys and Questionnaires
34
Blood Specimen Collection
24
enzalutamide
18
Radiotherapy
15
Docetaxel
15
Biopsy
14
Abiraterone Acetate
14
apalutamide
13
Leuprolide
13
Interviews as Topic
13
Observation
12
Magnetic Resonance Spectroscopy
12
Watchful Waiting
10
radium Ra 223 dichloride
9
darolutamide
9
Androgen Antagonists
9
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
8
Radiosurgery
7
Magnetic Resonance Imaging
7
Brachytherapy
7
abiraterone
6
Specimen Handling
6
Amplified Fragment Length Polymorphism Analysis
6
Triptorelin Pamoate
5
Standard of Care
5
Positron Emission Tomography Computed Tomography
5
Gonadotropin-Releasing Hormone
5
Focus Groups
5
Registries
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Prostatic Neoplasms
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled